Abstract: In the present invention, a novel 2-alkynyl-N9-propargyladenine represented by formula (I) wherein R1 represents a halogen atom, a furyl group, or a triazolyl group; R2 and R3 each represents a hydrogen atom or a C1-8 alkyl group, or form a cycloalkyl group by bonding to each other; and X represents a hydrogen atom or a hydroxyl group, or a pharmaceutically acceptable salt thereof, has a stronger and longer-lasting effect as a therapeutic agent for Parkinsonian syndromes.

Abstract: In a rectangular battery, a lead 9L connected to an electrode plate having a first polarity is connected to a battery case 1 which is an external terminal having the first polarity. A lead 11L connected to an electrode plate having a second polarity is connected to an external terminal 25 having the second polarity, through a connection plate 29. A distance between the battery case 1 and the connection plate 29 at at least one end of the battery case 1 in a long-side direction is equal to or less than the half of the width of the battery case 1 in a short-side direction thereof.

Abstract: Disclosed is a positive electrode for non-aqueous electrolyte secondary batteries, the positive electrode including a positive electrode material mixture layer which includes positive electrode active material particles and a binder. A curve representing a correlation between a distance from a current collector in the thickness direction of the positive electrode material mixture layer and an amount of the binder has a first maximum point, a minimum point, and a second maximum point. The minimum point corresponds to a position in a center area of the positive electrode material mixture layer in a thickness direction thereof, and the first and second maximum points correspond to a position nearer the current collector and a position further away from the current collector than the position corresponding to the minimum point, respectively.

Abstract: An insulating resin layer is formed on part of the surface of a current collector of an electrode plate for a battery. The insulating resin layer is formed on at least part of a portion at which a mixture particle is not in contact with the surface of the current collector, in the area in which an electrode mixture layer is formed on the surface of the current collector.

Abstract: To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress. The invention provides an anti-psychosocial stress agent containing, as an active ingredient, uridylic acid, uridine, or uracil. Since uridylic acid, uridine, or uracil, which is an active ingredient of the anti-psychosocial stress agent of the present invention, is inexpensively available and is a biological component, the agent exhibits high safety and can be continuously taken. Therefore, the anti-psychosocial stress agent of the present invention is effective for mitigating, alleviating, or relieving psychosocial stress, which is an issue in modern society. When the anti-psychosocial stress agent is taken before development of symptoms associated with psychosocial stress, the symptoms can be prevented.

Abstract: A lithium ion secondary battery including an electrode for a lithium ion secondary battery, the electrode including: a current collector 30; an electrode active material layer 31 being laminated on a surface of the current collector 30 and including an electrode active material 32 capable of absorbing and desorbing lithium ions; a lithium ion conductive layer 13 being laminated on a surface of the electrode active material layer 31, and including a lithium ion conductive gel swelled with a non-aqueous electrolyte; and a porous heat-resistant layer 14 being laminated on a surface of the lithium ion conductive layer 13, and including insulating metal oxide particles.

Abstract: To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress. The invention provides an anti-psychosocial stress agent containing, as an active ingredient, uridylic acid, uridine, or uracil. Since uridylic acid, uridine, or uracil, which is an active ingredient of the anti-psychosocial stress agent of the present invention, is inexpensively available and is a biological component, the agent exhibits high safety and can be continuously taken. Therefore, the anti-psychosocial stress agent of the present invention is effective for mitigating, alleviating, or relieving psychosocial stress, which is an issue in modern society. When the anti-psychosocial stress agent is taken before development of symptoms associated with psychosocial stress, the symptoms can be prevented.

Abstract: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5?-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

Abstract: The present invention relates to an agent for the prophylaxis or treatment of drug-induced neuropathy, which contains cytidine 5?-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of drug-induced neuropathy of the present invention shows a potent ameliorating effect on drug-induced neuropathy and is also superior in safety.

Abstract: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5?-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

Abstract: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5?-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

Abstract: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

Abstract: Medicinal compositions for treating eye diseases which contain as the active ingredient 2-alkynyladenosine derivatives having an acetylene union at the 2-position of adenine base. Having a long-lasting and remarkable effect of lowering ocular tension, these compositions are useful as remedies for eye diseases accompanying increased ocular tension or optic nerve failures, such as glaucoma and hypertonia oculi.

Abstract: Purine or triazolopurine compounds are disclosed represented by formula (I) or (II): ##STR1## wherein R.sup.1 and R.sup.4 represent each hydrogen, halogeno, hydroxy, mercapto, or amino; R.sup.2 represents alkyl or aryl; and R.sup.3 and R.sup.5 represent each hydrogen, alkyl, or aryl; and pharmaceutical compositions comprising these compounds as xanthine oxidase inhibitors, remedies for hyperuricemia, or remedies or preventive agents for gout.